Skip to main content
. Author manuscript; available in PMC: 2015 Jan 7.
Published in final edited form as: Neuron. 2014 Nov 5;84(3):608–622. doi: 10.1016/j.neuron.2014.10.038

Figure 2.

Figure 2

Updated staging framework for preclinical AD (adapted from Sperling et al. 2011a with updates from Jack et al. 2012). Stage 0 represents individuals without biomarker abnormalities who are not thought to be on the AD trajectory. Stage 1 begins with cerebral amyloidosis; Stage 2 is amyloidosis plus markers of neurodegeneration; Stage 3 is amyloidosis + neurodegeneration + evidence of subtle cognitive and behavioral decline that is not yet sufficient to meet criteria for mild cognitive impairment or dementia due to AD. SNAP or Suspected Non-Alzheimer Pathology has evidence of neurodegeneration without apparent amyloidosis.